Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors
Publication information:
Bleicher I, Rossin E, Vavvas D. Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors.
JAMA Ophthalmol. 2022;140(7):745–746. PMID: 35616947